Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisodamine SCHEMBL29353530 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL27981908 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL30679509 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL31098813 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL28725258 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL620576 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Anisodamine SCHEMBL30679510 | 1.00 | CHRM1 (0.72) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL16167837 | 0.84 | CHRM1 (0.76) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL8854381 | 0.84 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL41317 | 0.84 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-12616688-B2 | Cell glycocalyx protection effect of anisodamine | CHENGDU FIRST PHARMACEDTICAL CO., LTD (CN) | 2026-05-05 | — | — | US | disclosed |
| WO-2026051786-A1 | USE OF ANISODAMINE HYDROBROMIDE | 成都第一制药有限公司 | 2026-03-12 | — | — | WO | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| CN-119326761-B | Application of anisodamine hydrobromide in preparing medicine for preventing and/or treating cisplatin ototoxicity | 成都第一制药有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119326761-A | Application of anisodamine hydrobromide in preparing medicine for preventing and/or treating cisplatin ototoxicity | 成都第一制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| US-20230321072-A1 | CELL GLYCOCALYX PROTECTION EFFECT OF ANISODAMINE | CHENGDU FIRST PHARMACEDTICAL CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616688-B2 | Cell glycocalyx protection effect of anisodamine | CD14, ICAM1, VCAM1 | CHRM1 1006/4885CHRM2 2061/4885CHRM5 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.